On April 15, Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) ( Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) . SH), whose share price plunged the day before because the World Health Organization (who) approved the “single dose” HPV vaccination program, quickly recovered. On that day, the share price closed at 269.10 yuan, up 4.47%, with a total market value of 163354 billion yuan.
On the same day, the company disclosed the first quarter report of 2022. At the performance level, the dividend brought by the promotion of HPV cervical cancer vaccine continues to break out.
During the reporting period, the company achieved an operating revenue of 3.171 billion yuan, a year-on-year increase of 284.85%; The net profit attributable to shareholders of listed companies was 1.331 billion yuan, a year-on-year increase of 360.18%, and the net profit attributable to shareholders of listed companies after deducting non recurring profits and losses was 1.315 billion yuan, a year-on-year increase of 367.75%. The basic earnings per share was 2.19 yuan / share, a year-on-year increase of 356.25%.
The company said that the surge in revenue and net profit was mainly due to the increase in income from bivalent cervical cancer vaccines, reagents and active raw materials.
Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) 2021 achieved revenue of 5.75 billion yuan, a year-on-year increase of 144.25%; The net profit attributable to shareholders of listed companies was 2.021 billion yuan, a year-on-year increase of 198.59%. Four quarters of revenue and net profit broke the highest value in the company’s history. In the first quarter of 2022, compared with the fourth quarter of 2021, the revenue and net profit increased by about 50% and 60% month on month.
In terms of share price, Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) has been in a tortuous upward trend since 2022, and once hit the highest price of 290 yuan in the year on April 12. On April 14, affected by the “single dose” HPV vaccination plan issued and approved by the World Health Organization, the Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) session, as a giant of HPV vaccine, staged a “big dive”, closing at 257.59 yuan / share on the same day, with a market value of 16.3 billion yuan evaporated.
In this regard, in the emergency response, Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) said that the bivalent HPV vaccine currently approved by the company in China is three doses (women aged 9-14 can take two doses). Under the current national drug administration policy, a series of clinical, data support and registration change procedures need to be performed if the inoculation grade change is carried out, which will take a certain time, and will not have a significant impact on the company’s business performance in the short term.
Soochow Securities Co.Ltd(601555) medical team also pointed out in the comments: the antibody titer produced by one dose of HPV vaccine is lower than 2 or 3 doses. Although one dose of HPV vaccine can provide better protection against HPV-16 / 18 infection, the current evidence is difficult to completely replace two or three doses of HPV vaccine, and there is still lack of more evidence on the protection efficiency of other types of HPV infection other than HPV-16 / 18, Therefore, three needle vaccination is always the best way of protection and proved by sufficient clinical evidence.
The interface news reporter noted that in order to expand the global coverage of HPV vaccination for women, the who published a white paper on the single dose HPV vaccination plan as early as 2018, which is committed to improving the HPV vaccination rate in the world, especially in low-income countries.
The above comments believe that the news is a public welfare proposal of the who, a protective proposal for women in some poor countries with very low HPV vaccine coverage, and has no impact on the standard vaccination procedure of three shot vaccine in China in the short term.
It is worth mentioning that under the continuous surge of performance, despite the rise of stock price band, many institutions still increased their positions in the first quarter of 2022. Among them, Hong Kong Central Clearing Co., Ltd. (northbound capital) increased its positions for three consecutive quarters, continued to increase its holdings of 3.4234 million shares, and held 1.52% of the company’s shares at the end of the first quarter, ranking the fifth largest shareholder.
China Merchants Guozheng biomedical index graded securities investment fund holds 2.5617 million shares of the company, and Gelan Trading China Europe medical and health hybrid securities investment fund holds 2.4809 million shares, which is among the top ten new circulating shareholders.
In addition, in the first quarter of this year, Ding Jinglin, the outgoing supervisor of the company, continued to reduce his holdings of 3.627 million shares, with a cumulative reduction of more than 5 million shares compared with the end of the third quarter of 2021. Li Yimin, another chief engineer of the company, also reduced his holdings for two consecutive quarters, reducing 300000 shares in the first quarter.
